Effects of carboxyamidotriazole on in vi
β
Riccardo Alessandro; Simona Fontana; Margherita Giordano; Chiara Corrado; Paolo
π
Article
π
2008
π
John Wiley and Sons
π
English
β 468 KB
## Abstract Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcrβablβdriven CML cells may provide a feasible opt